NASDAQ:ASLN - ASLAN PHARMACEU/ADR Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ASLAN PHARMACEU/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.13 -0.04 (-3.42 %) (As of 03/27/2020 04:00 PM ET) Add Compare Today's Range$1.10Now: $1.13▼$1.2250-Day Range$0.94MA: $1.74▼$2.1952-Week Range$0.35Now: $1.13▼$8.18Volume44,469 shsAverage Volume165,748 shsMarket Capitalization$36.22 millionP/E RatioN/ADividend YieldN/ABeta2.66 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASLN Previous Symbol CUSIPN/A CIKN/A Webhttp://aslanpharma.com/ Phone65-6222-4235Debt Debt-to-Equity Ratio1.12 Current Ratio4.14 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3 million Price / Sales12.07 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-56.50Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-47,070,000.00 Net MarginsN/A Return on Equity-129.37% Return on Assets-66.68%Miscellaneous EmployeesN/A Outstanding Shares32,050,000Market Cap$36.22 million Next Earnings Date5/4/2020 (Estimated) OptionableNot Optionable Receive ASLN News and Ratings via Email Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ASLN Rates by TradingView ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions How has ASLAN PHARMACEU/ADR's stock been impacted by COVID-19 (Coronavirus)? ASLAN PHARMACEU/ADR's stock was trading at $1.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ASLN stock has decreased by 28.9% and is now trading at $1.13. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ASLAN PHARMACEU/ADR? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ASLAN PHARMACEU/ADR. When is ASLAN PHARMACEU/ADR's next earnings date? ASLAN PHARMACEU/ADR is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for ASLAN PHARMACEU/ADR. What price target have analysts set for ASLN? 3 Wall Street analysts have issued 1 year price targets for ASLAN PHARMACEU/ADR's stock. Their forecasts range from $5.00 to $8.00. On average, they expect ASLAN PHARMACEU/ADR's stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 460.5% from the stock's current price. View analysts' price targets for ASLAN PHARMACEU/ADR. Has ASLAN PHARMACEU/ADR been receiving favorable news coverage? News coverage about ASLN stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ASLAN PHARMACEU/ADR earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next several days. View the latest news aboutASLAN PHARMACEU/ADR. Who are some of ASLAN PHARMACEU/ADR's key competitors? Some companies that are related to ASLAN PHARMACEU/ADR include MediciNova (MNOV), Evelo Biosciences (EVLO), Humanigen (HGEN), Tyme Technologies (TYME), Agile Therapeutics (AGRX), Aeglea Bio Therapeutics (AGLE), Kalvista Pharmaceuticals (KALV), Cerecor (CERC), Paratek Pharmaceuticals (PRTK), Fortress Biotech (FBIO), Newron Pharmaceuticals (NWPHF), vTv Therapeutics (VTVT), Avenue Therapeutics (ATXI), Helix Biopharma (HBPCF) and TAIWAN LIPOSOME/S (TLC). What other stocks do shareholders of ASLAN PHARMACEU/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN PHARMACEU/ADR investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Onconova Therapeutics (ONTX), Opko Health (OPK), Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Cidara Therapeutics (CDTX), Ocugen (OCGN) and Cassava Sciences (SAVA). Who are ASLAN PHARMACEU/ADR's key executives? ASLAN PHARMACEU/ADR's management team includes the following people: Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)Mr. Kiran Asarpota, VP of Fin. (Age 40)Charlie Hsu, Investor Relations DirectorMr. Ben Goodger, Gen. Counsel (Age 56)Chi-Chin Wang, IR & Corp. Devel. Director When did ASLAN PHARMACEU/ADR IPO? (ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. What is ASLAN PHARMACEU/ADR's stock symbol? ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN." Who are ASLAN PHARMACEU/ADR's major shareholders? ASLAN PHARMACEU/ADR's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Marshall Wace LLP (0.30%), Bank of America Corp DE (0.25%), Virtu Financial LLC (0.17%) and Renaissance Technologies LLC (0.05%). Which major investors are buying ASLAN PHARMACEU/ADR stock? ASLN stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of America Corp DE, Virtu Financial LLC, and Renaissance Technologies LLC. How do I buy shares of ASLAN PHARMACEU/ADR? Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ASLAN PHARMACEU/ADR's stock price today? One share of ASLN stock can currently be purchased for approximately $1.13. How big of a company is ASLAN PHARMACEU/ADR? ASLAN PHARMACEU/ADR has a market capitalization of $36.22 million and generates $3 million in revenue each year. The company earns $-47,070,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. View additional information about ASLAN PHARMACEU/ADR. What is ASLAN PHARMACEU/ADR's official website? The official website for ASLAN PHARMACEU/ADR is http://aslanpharma.com/. How can I contact ASLAN PHARMACEU/ADR? ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected] MarketBeat Community Rating for ASLAN PHARMACEU/ADR (NASDAQ ASLN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 162 (Thanks for Voting!)Underperform Votes: 194 (Thanks for Voting!)Total Votes: 356MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEU/ADR and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/28/2020 by MarketBeat.com StaffFeatured Article: What are Institutional Investors?
